Teva Pharmaceutical Industries Ltd.'s neurology portfolio is showing renewed growth and the company is looking to build on that foundation with the addition of two new pipeline assets, in a deal announced ahead of its third quarter sales and earnings release.
The company announced a worldwide licensing and development deal with MODAG GmbH on 26 October, gaining rights to two...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
